找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases; Christopher L. Cioffi Book 2020 Springer Nature Switzerlan

[復(fù)制鏈接]
樓主: INFER
11#
發(fā)表于 2025-3-23 12:00:09 | 只看該作者
Topics in Medicinal Chemistryhttp://image.papertrans.cn/e/image/283037.jpg
12#
發(fā)表于 2025-3-23 15:46:13 | 只看該作者
Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases978-3-030-56619-7Series ISSN 1862-2461 Series E-ISSN 1862-247X
13#
發(fā)表于 2025-3-23 22:03:01 | 只看該作者
1862-2461 re therapeutic opportunities for age-related macular degener.This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited R
14#
發(fā)表于 2025-3-24 00:00:31 | 只看該作者
Book 2020ed Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases..Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected t
15#
發(fā)表于 2025-3-24 02:33:52 | 只看該作者
16#
發(fā)表于 2025-3-24 08:49:39 | 只看該作者
17#
發(fā)表于 2025-3-24 13:45:57 | 只看該作者
https://doi.org/10.1007/978-3-662-36243-3ts; (2) new and emerging therapies for primary open angle glaucoma (POAG) in both the clinical and pre-clinical stages (the review of emerging glaucoma therapies highlighted in this chapter is limited to those for which in vivo efficacy data were published); and (3) progress toward treating the underlying optic neuropathy, which defines glaucoma.
18#
發(fā)表于 2025-3-24 15:52:26 | 只看該作者
19#
發(fā)表于 2025-3-24 21:08:22 | 只看該作者
20#
發(fā)表于 2025-3-25 01:23:54 | 只看該作者
Emerging Therapeutic Modalities for Diabetic Retinopathy,to improve tissue penetration and cell selectivity. We report here on selected novel ocular drug delivery technologies and therapeutic modalities, and their potential as game-changing clinical approaches for addressing the sight-threatening complications of diabetes.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-26 11:01
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
阳高县| 富平县| 沙雅县| 洛宁县| 乌兰浩特市| 肇州县| 昌江| 北川| 靖边县| 海晏县| 云龙县| 陇南市| 丹棱县| 老河口市| 晋宁县| 丰顺县| 鄢陵县| 铅山县| 家居| 田林县| 岱山县| 延长县| 三河市| 荣昌县| 翼城县| 永川市| 澜沧| 分宜县| 纳雍县| 门源| 大丰市| 个旧市| 新源县| 松江区| 黄冈市| 江川县| 保山市| 信宜市| 南溪县| 漳浦县| 舒城县|